PATENT CLAIM ANALYSIS

Application Number: 15990313
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "450000"]

Abstract:
Compositions which comprise a liposomal camptothecin and optionally liposomal fluoropyrimidine and a targeted antitumor agent are useful in achieving enhanced therapeutic effects when combinations of these agents are administered.

Claim (Index 8):
A method to treat cancer in a subject, which method comprises administering to a subject in need of said treatment a composition comprising\n (a) liposomes associated with at least one water-soluble camptothecin; and (b) an antiangiogenic targeted antitumor agent which is a compound that decreases or inhibits the activity of an epidermal growth factor family receptor (EGFR) tyrosine kinase or that inhibits the activity of a vascular endothelial growth factor (VEGF) receptor tyrosine kinase or that binds to VEGF; for use in treating a cancer in a subject.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 93.0
- Lexical Diversity: 1.15385
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['09807332', '14352662', '15891170', '10417631', '14990167']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.731227035041111
- 35 USC 102 Novelty (BERT): 0.5016301854178717
- Combined Prediction Score: 0.708267350078787
- Mean Citation Score: 213.047808
- Max Citation Score: 223.26814
- Similarity Product: 142.04871581859587

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test